Key result
Synthetic platelet nanoparticles reduced blood loss by 35% in mice with von Willebrand disease type 2B and by 68% in VWF-knockout mice during a tail-clip assay.
Why the study?
Innovation in von Willebrand disease has been limited, creating a need to move beyond plasma-derived or recombinant von Willebrand factor replacement therapies.
Does treatment with synthetic platelet nanoparticles reduce bleeding and improve thrombus formation in murine models of von Willebrand disease?
Does treatment with synthetic platelet nanoparticles reduce bleeding and improve thrombus formation in murine models of von Willebrand disease?
Answers are grounded in this paper and cite their sources.
Synthetic platelet nanoparticles significantly reduce blood loss and improve clot formation in murine models of von Willebrand disease, representing a potential novel alternative to standard replacement therapies.
The lack of innovation in von Willebrand disease (VWD) originates from many factors including the complexity and heterogeneity of the disease but also from a lack of recognition of the impact of the bleeding symptoms experienced by patients with VWD. Recently, a few research initiatives aiming to move past replacement therapies using plasma-derived or recombinant von Willebrand factor (VWF) concentrates have started to emerge. Here, we report an original approach using synthetic platelet (SP) nanoparticles for the treatment of VWD type 2B (VWD-2B) and severe VWD (type 3 VWD). SP are liposomal nanoparticles decorated with peptides enabling them to concomitantly bind to collagen, VWF, and activated platelets. In vitro, using various microfluidic assays, we show the efficacy of SPs to improve thrombus formation in VWF-deficient condition (with human platelets) or using blood from mice with VWD-2B and deficient VWF (VWF-KO, ie, type 3 VWD). In vivo, using a tail-clip assay, SP treatment reduced blood loss by 35% in mice with VWD-2B and 68% in mice with VWF-KO. Additional studies using nanoparticles decorated with various combinations of peptides demonstrated that the collagen-binding peptide, although not sufficient by itself, was crucial for SP efficacy in VWD-2B; whereas all 3 peptides appeared necessary for mice with VWF-KO. Clot imaging by immunofluorescence and scanning electron microscopy revealed that SP treatment of mice with VWF-KO led to a strong clot, similar to those obtained in wild-type mice. Altogether, our results show that SP could represent an attractive therapeutic alternative for VWD, especially considering their long half-life and stability.
No takes yet. Share an insight, caveat, or question.
Roullet et al. (2023) studied Von Willebrand disease. Synthetic platelet (SP) nanoparticles was evaluated on Blood loss in a tail-clip assay (35% reduction (VWD-2B) and 68% reduction (VWF-KO)). Synthetic platelet nanoparticles reduced blood loss by 35% in mice with von Willebrand disease type 2B and by 68% in VWF-knockout mice during a tail-clip assay.
Synapse has enriched 10 related papers. Consider them for comparative context: